This document provides information about an upcoming Immuno-Oncology conference, including workshops, speakers, and program details. The conference will take place September 25-27, 2018 in London and will feature discussions on novel targeted cancer therapies. It will include workshops on strategic intelligence in immuno-oncology and the microbiome's role in cancer immunotherapy. The two-day main conference will discuss topics like immune checkpoints, oncolytic viruses, bispecific antibodies, and combination therapies. It aims to foster thought-provoking discussions in this space.
1) TapImmune is developing T-cell immunotherapies focused on breast and ovarian cancers. Their lead candidate, TPIV 200, is in four Phase 2 clinical trials.
2) They are also developing TPIV 110 for HER2-positive breast cancer and plan to file an IND in 2017. Additionally, their PolyStart technology aims to enhance DNA vaccines and is being evaluated preclinically.
3) TapImmune's strategy in 2017 is to complete ongoing Phase 2 trials, seek partners for late-stage development and commercialization, explore combination regimens, and seek opportunities to monetize PolyStart.
We enable UK life science companies to develop their drug discovery projects. And through networks of expert labs and CROs our Virtual R&D team can access and provide:
> industrially rigorous advice in drug discovery
> clinical and commercial insight
> expertise in delivery and project management
If you are an SME with a drug discovery project, or a CRO with expertise to provide, attend this event and find out how we can help you.
This document provides information on the 3rd Annual Conference on Cancer Vaccines taking place on September 15-17, 2014 in London.
The chair for 2014 will be Dr. Joseph Melenhorst from the University of Pennsylvania. Key speakers will discuss developments in cancer immunotherapy from organizations like Amgen, Immatics GmbH, DanDrit Biotech, and the University of Southampton.
Attendees will learn about a collaboration between the University of Pennsylvania and Novartis assessing T cell immunotherapy techniques. Presentations will also evaluate oncolytic vaccines from Amgen and Psioxus Therapeutics, and key questions in cancer immunotherapy from the University of Southampton. Analytical advances for cancer vaccines will be discussed from
This document provides information about the Cell & Gene Therapy conference taking place on October 10-11, 2018 in London. It includes details about the agenda, speakers, workshops, and registration information. The two-day conference will focus on topics related to manufacturing, regulation, and translational research of cell and gene therapies. There will be presentations from industry experts on developing stem cell and gene therapies, as well as workshops on practical development issues and competitive intelligence in the cell and gene therapy field.
This document provides information about a clinical quality and compliance masterclass conference taking place on June 16th and 17th, 2016 in Vienna. The conference will focus on managing clinical quality for greater compliance, effectiveness, and audit readiness. Over the two days, there will be keynote speakers from major pharmaceutical companies, case studies, and workshops on topics such as on-site quality improvements, inspection readiness, quality risk management, and third-party oversight. Attendees will include quality assurance professionals from pharmaceutical and biotech companies as well as CROs.
In its third year, “PEGS China: Protein and Antibody Engineering & Development Summit” returns to Shanghai for 3 days of inspiring presentations and case studies featuring the latest trends and future potential of China’s biotech industry.
This year’s event comprises four content-driven conferences with over sixty global speakers, plus a new 1-day seminar on clinical & regulatory strategies for global and domestic IND and BLA filings. In addition, dedicated exhibit hall and poster viewing hours will provide invaluable opportunities for networking, deal-making and ideas exchange.
Precision Medicine & Biomarkers Leaders Summit - Boston USA - 7th & 8th MayTony Couch
Tracks focus on R&D strategies, Biomarker development, Immuno-oncology, CDx development, AI and Big data analysis and approaches – Attending this Summit will provide you with the opportunity to mix and interact with experts working in all facets of Precision Medicine through the individual, panel and roundtable discussions on offer.
This document provides information about the 4th annual ADC Summit 2015 conference organized by SMi that will take place from May 18-19, 2015 in London. The conference will focus on advancing antibody-drug conjugate (ADC) and radioimmunotherapy (RIT) therapies, with sessions on payload development, clinical trials of ADCs, small molecule approaches, and intellectual property issues. There will also be a half-day workshop on May 20 about the regulatory requirements and development process for ADCs.
1) TapImmune is developing T-cell immunotherapies focused on breast and ovarian cancers. Their lead candidate, TPIV 200, is in four Phase 2 clinical trials.
2) They are also developing TPIV 110 for HER2-positive breast cancer and plan to file an IND in 2017. Additionally, their PolyStart technology aims to enhance DNA vaccines and is being evaluated preclinically.
3) TapImmune's strategy in 2017 is to complete ongoing Phase 2 trials, seek partners for late-stage development and commercialization, explore combination regimens, and seek opportunities to monetize PolyStart.
We enable UK life science companies to develop their drug discovery projects. And through networks of expert labs and CROs our Virtual R&D team can access and provide:
> industrially rigorous advice in drug discovery
> clinical and commercial insight
> expertise in delivery and project management
If you are an SME with a drug discovery project, or a CRO with expertise to provide, attend this event and find out how we can help you.
This document provides information on the 3rd Annual Conference on Cancer Vaccines taking place on September 15-17, 2014 in London.
The chair for 2014 will be Dr. Joseph Melenhorst from the University of Pennsylvania. Key speakers will discuss developments in cancer immunotherapy from organizations like Amgen, Immatics GmbH, DanDrit Biotech, and the University of Southampton.
Attendees will learn about a collaboration between the University of Pennsylvania and Novartis assessing T cell immunotherapy techniques. Presentations will also evaluate oncolytic vaccines from Amgen and Psioxus Therapeutics, and key questions in cancer immunotherapy from the University of Southampton. Analytical advances for cancer vaccines will be discussed from
This document provides information about the Cell & Gene Therapy conference taking place on October 10-11, 2018 in London. It includes details about the agenda, speakers, workshops, and registration information. The two-day conference will focus on topics related to manufacturing, regulation, and translational research of cell and gene therapies. There will be presentations from industry experts on developing stem cell and gene therapies, as well as workshops on practical development issues and competitive intelligence in the cell and gene therapy field.
This document provides information about a clinical quality and compliance masterclass conference taking place on June 16th and 17th, 2016 in Vienna. The conference will focus on managing clinical quality for greater compliance, effectiveness, and audit readiness. Over the two days, there will be keynote speakers from major pharmaceutical companies, case studies, and workshops on topics such as on-site quality improvements, inspection readiness, quality risk management, and third-party oversight. Attendees will include quality assurance professionals from pharmaceutical and biotech companies as well as CROs.
In its third year, “PEGS China: Protein and Antibody Engineering & Development Summit” returns to Shanghai for 3 days of inspiring presentations and case studies featuring the latest trends and future potential of China’s biotech industry.
This year’s event comprises four content-driven conferences with over sixty global speakers, plus a new 1-day seminar on clinical & regulatory strategies for global and domestic IND and BLA filings. In addition, dedicated exhibit hall and poster viewing hours will provide invaluable opportunities for networking, deal-making and ideas exchange.
Precision Medicine & Biomarkers Leaders Summit - Boston USA - 7th & 8th MayTony Couch
Tracks focus on R&D strategies, Biomarker development, Immuno-oncology, CDx development, AI and Big data analysis and approaches – Attending this Summit will provide you with the opportunity to mix and interact with experts working in all facets of Precision Medicine through the individual, panel and roundtable discussions on offer.
This document provides information about the 4th annual ADC Summit 2015 conference organized by SMi that will take place from May 18-19, 2015 in London. The conference will focus on advancing antibody-drug conjugate (ADC) and radioimmunotherapy (RIT) therapies, with sessions on payload development, clinical trials of ADCs, small molecule approaches, and intellectual property issues. There will also be a half-day workshop on May 20 about the regulatory requirements and development process for ADCs.
SMi Group's 7th annual Biosimilars Europe 2016 conferenceDale Butler
This document provides information about two pre-conference workshops for the 7th Annual Biosimilars Europe conference.
The first workshop focuses on maximizing intellectual property and regulatory rights related to biosimilars. It will cover topics like regulatory data protection, orphan drug exclusivity, supplementary protection certificates, and pediatric rewards. The workshop leaders are partners at Bristows LLP.
The second workshop examines how the payer environment for biosimilars is evolving. It will provide insight into pricing, reimbursement, and formulary access processes. Case studies will also be presented on successful biosimilar launches. The workshop leader is the director of RJW & Partners Ltd, a pricing and market
The document is a report on the state of the UK drug discovery industry in 2019. It finds that most small and medium enterprises in the industry are service and supply companies, employing fewer than 20 people. The majority of drug development assets held by UK companies are focused on cancer, anti-infectives, and central nervous system disorders. Artificial intelligence and cell and gene therapies are seen as promising but in need of further validation and data. The report recommends that the government increase funding support and that the Medicines Discovery Catapult continue connecting companies, providing access to datasets and technologies, and helping to validate new models like complex cell models.
Precision Medicine & Biomarkers Leaders Summit - Boston USA - 7th & 8th MayTony Couch
Global Engage is pleased to announce the 2018 Precision Medicine & Biomarkers Leaders Summit USA taking place on May 7-8th in Boston, MA. The event is part of our highly successful Drug Discovery Series which includes conferences on Biologics, Medicinal Chemistry, NASH, Pharmaceutical R&D IT and the Human Microbiome amongst others. It is also the sister meeting of the European Precision Medicine Summit which has run successfully since 2013.
This presentation provides an overview of Pressure BioSciences, Inc. Key points include:
- PBI develops instruments and consumables for pressure cycling technology (PCT) sample preparation. PCT uses repeated high-pressure cycles to control molecular interactions.
- PBI's primary market is the biopharma industry, where PCT systems are used from biomarker discovery through validation and quality control. Over 270 PCT systems have been installed.
- A new next-generation PCT instrument, the Barocycler 2320EXTREME, was recently released.
- PBI is also developing ultra-shear technology to produce nanoemulsions for applications in food, pharmaceuticals, and other
This press release summarizes a collaboration between UCB and Domainex to develop cancer drugs targeting MEK protein. Using Domainex's protein engineering technology, they were able to identify a form of MEK suitable for structural analysis. This provided UCB with high-resolution structural information to design a novel class of MEK inhibitor molecules with potential to treat cancer. The collaboration validated Domainex's technology in rapidly solving challenges in identifying drug targets.
Global peptide cancer vaccine market & clinical pipeline insightRajesh Sarma
“Global Peptide Cancer Vaccine Market & Clinical Pipeline Insight” Report Highlights:
Introduction to Peptide cancer Vaccine
Mechanism of Action of Peptide Cancer Vaccine
Need of Peptide Cancer Vaccines
Clinical Trials Efficacy Study of Synthetic Peptide Analog Obtained From WT1 Oncoprotein
Wide Spectrum Action of Peptide Cancer Vaccines against Major Cancer
Global Peptide Cancer Vaccine Pipeline: 41 Vaccines
Global Peptide Cancer Vaccine Clinical Pipeline by Company, Indication & Phase
The document discusses Strand Genomics Inc., which offers genomic analysis and clinical interpretation software and services. It focuses on personalized medicine by using its StrandOmics platform to analyze genomic data and determine disease risks for individuals. StrandOmics aims to make genomic testing routine in medical care to help clinicians make more informed decisions. Strand has grown to over 200 scientists and serves over 2,000 labs and 100,000 patients. Its partnership with Health Care Global Enterprises successfully piloted cancer risk assessment and molecular diagnosis for over 50 patients in India.
A biomarker strategy aims to answer key clinical questions to support drug development through identifying and testing biomarkers. Developing a robust biomarker strategy can mitigate risks and inform clinical study design by generating testable hypotheses to bridge pre-clinical and clinical research. Effective biomarker strategies consider assay suitability, study design, and sample availability to reliably detect biomarkers and provide statistically meaningful results. Emerging technologies allow deeper interrogation of drugs and disease through multiplexed readouts to enhance biomarker discovery and clinical development.
This document provides information about an upcoming conference on immunogenicity taking place from June 12-13, 2017 in London. The conference will focus on standardizing immunogenicity methods, regulatory considerations, novel approaches to reducing immunogenicity, developments for biologic drugs and immunogenicity predictions, and emerging solutions. It lists the program agenda with topics such as predictive tools for immunogenicity, reporting clinically relevant data, cut point setting, EU guidance, ADA-dependent reactions, personalizing therapy, tolerogenic nanoparticles, and a panel on human versus humanized antibodies. Speakers are from organizations like Regeneron, NIBSC, EpiVax, Novartis, Abbvie, Merck, Roche, and Immun
The document discusses the potential for genetic testing in sports. It provides examples of genes linked to athletic performance, such as the ACTN3 gene which is associated with sprint performance. Countries like Uzbekistan are exploring genetic screening programs to identify children suited for certain sports. However, genes only explain some variability in athletic traits, as environment and training also play large roles. While certain physical attributes are genetically determined, such as height, other factors like speed can be improved through training, but individual ability to gain benefits from practice is also genetic. Overall, the document examines both the genetic and non-genetic influences on athleticism and the emerging use of genetics in sports identification and training programs.
This document discusses how in vivo imaging can be used to understand the distribution of candidate compounds in the body. It provides examples of how various imaging modalities such as positron emission tomography (PET), near infrared imaging, and mass spectrometry imaging can be used to track the accumulation of compounds in organs, penetration into tissues, and ability to cross barriers like the blood brain barrier. The document emphasizes how imaging can accelerate drug development by providing visualization of biological processes and quantifying pharmacokinetics, target engagement, and toxicity.
This document provides information about the 3rd Annual Conference on Drug Discovery Chemistry hosted by SMi Group. The conference will take place on March 18-19, 2019 in London, UK, with a half-day workshop on March 20. Key speakers will discuss topics such as novel drug modalities, targeting difficult proteins, using artificial intelligence in drug discovery, and optimizing drug discovery techniques. Attendees can learn about recent advances, network with industry leaders, and explore strategic partnerships. Discounts are available for early registration.
World ADC Frankfurt 2015 - sample brochureWorld ADC
The World ADC Frankfurt meeting has been established with the simple mission of speeding up the development of more potent and safe antibody drug conjugates.
Learn not only how to make an ADC, but how to make a great one. With insights on numerous novel payload technologies, robust strategies for preclinical evaluation and emerging clinical data, there is no better opportunity to accelerate your research.
We can aid decision making from the pre-clinical to the clinical setting, supporting line of sight to the clinic, by identifying and translating crucial biomarker approaches into the real world.
Ourotech is developing a hydrogel that mimics tumor microenvironments to test cancer drug resistance outside the body. Their solution involves obtaining tumor samples, growing them in a 96-well plate using the proprietary hydrogel, testing drug and combination treatments, and calculating human dosages. This allows personalized cancer treatment by determining the most effective drugs without trial and error. They have proof of concept data showing their hydrogel can better predict drug resistance compared to other methods. With $1.5M funding, they plan to finish preclinical trials, seek FDA clearance, generate revenue from pharmaceutical clients, and further develop the technology.
The document summarizes the work and goals of OncoPlex Diagnostics, a biotechnology company that uses mass spectrometry and liquid tissue technology to develop cancer diagnostic assays. It thanks various mentors and colleagues for their support of the author's internship. OncoPlex aims to establish standardized protein profiling as the standard for personalized cancer treatment by overcoming challenges such as physician education and product differentiation. The marketing department seeks to increase awareness of OncoPlex's technology by creating deliverables like sales sheets and letters for physicians.
This document announces a professional development session on the pharmaceuticals dashboard for 2021. It will discuss topics like uncertainty in quality, the future of manufacturing and regulations, and competitiveness with trade barriers. The session aims to help professionals mature their skills and align with emerging expectations. It will use tutorials, discussions, examples and case studies. Participant assessment will be confidential. The session facilitators have extensive regulatory experience in Pakistan and international agencies. It will be held on December 19th in Karachi with a small group size.
The Cell Therapy Catapult was established to help grow the UK cell therapy industry by providing facilities, expertise, and funding for collaboration between researchers and industry. It has laboratories and teams working on process development, clinical trials, and business development. In its first year it has over 60 staff and is engaged in both small and large collaborative projects. The goal is to deliver life-changing cell therapies and investible projects that help establish UK leadership in this industry.
SMi Group's Adaptive Designs in Clinical Trials conferenceDale Butler
This document summarizes an upcoming conference on adaptive designs in clinical trials taking place from April 20-21, 2015 in London. The conference will focus on topics such as Bayesian adaptive designs, subgroup selection in clinical trials, integrating real-world patient data into adaptive trials, and designing biomarker-driven multi-arm multi-stage cancer trials. Speakers will discuss challenges with adaptive designs and their use in different therapeutic areas like neurodegenerative diseases. Participants can also register for optional half-day workshops on April 22nd focusing on Bayesian clinical trial designs and navigating international regulatory landscapes for adaptive trials.
This is part of the MaRS BioEntrepreneurship series.
Speaker: Lynne Zydowsky, Ph.D., Managing Principal Zydowsky Consultants
* Explore the development of regulated drugs and devices
* Understand where and how value is generated in the pharmaceuticals industry
* Appreciate the interplay between science and business in a biotech company
To download a copy of the audio for this presentation, please go to:
http://www.marsdd.com/bioent/oct16
For the event blog and Q+A, please see:
http://blog.marsdd.com/2006/10/17/bringing-together-art-and-science/
This document provides information about an upcoming conference on immunogenicity taking place June 13-14, 2016 in London. It lists the schedule, speakers, and topics to be covered over the two days. The conference will explore approaches to standardizing immunogenicity assays, unwanted immunogenicity, integrating immunogenicity risk data to predict clinical outcomes, and other topics related to assessing and reducing the immunogenicity of biotherapeutics. Registration discounts are available by March 31st or April 29th. The conference is aimed at accelerating the commercialization of next generation biotherapeutics by adopting advanced immunogenicity assessments.
This document provides information about an upcoming conference on immunogenicity to be held June 13-14, 2016 in London. It includes an overview of the conference sessions and speakers. The sessions will cover topics such as approaches to standardizing drug level and anti-drug antibody assays, unwanted immunogenicity, integrating immunogenicity risk data, immunogenicity of biologics and biosimilars, and the role of aggregation in immunogenicity. There will also be two half-day post-conference workshops on June 15 on standardizing assays for biotherapeutics and unwanted immunogenicity from the bench to the bedside. The conference is aimed at accelerating development and approval of next generation biotherapeutics by adopting
SMi Group's 7th annual Biosimilars Europe 2016 conferenceDale Butler
This document provides information about two pre-conference workshops for the 7th Annual Biosimilars Europe conference.
The first workshop focuses on maximizing intellectual property and regulatory rights related to biosimilars. It will cover topics like regulatory data protection, orphan drug exclusivity, supplementary protection certificates, and pediatric rewards. The workshop leaders are partners at Bristows LLP.
The second workshop examines how the payer environment for biosimilars is evolving. It will provide insight into pricing, reimbursement, and formulary access processes. Case studies will also be presented on successful biosimilar launches. The workshop leader is the director of RJW & Partners Ltd, a pricing and market
The document is a report on the state of the UK drug discovery industry in 2019. It finds that most small and medium enterprises in the industry are service and supply companies, employing fewer than 20 people. The majority of drug development assets held by UK companies are focused on cancer, anti-infectives, and central nervous system disorders. Artificial intelligence and cell and gene therapies are seen as promising but in need of further validation and data. The report recommends that the government increase funding support and that the Medicines Discovery Catapult continue connecting companies, providing access to datasets and technologies, and helping to validate new models like complex cell models.
Precision Medicine & Biomarkers Leaders Summit - Boston USA - 7th & 8th MayTony Couch
Global Engage is pleased to announce the 2018 Precision Medicine & Biomarkers Leaders Summit USA taking place on May 7-8th in Boston, MA. The event is part of our highly successful Drug Discovery Series which includes conferences on Biologics, Medicinal Chemistry, NASH, Pharmaceutical R&D IT and the Human Microbiome amongst others. It is also the sister meeting of the European Precision Medicine Summit which has run successfully since 2013.
This presentation provides an overview of Pressure BioSciences, Inc. Key points include:
- PBI develops instruments and consumables for pressure cycling technology (PCT) sample preparation. PCT uses repeated high-pressure cycles to control molecular interactions.
- PBI's primary market is the biopharma industry, where PCT systems are used from biomarker discovery through validation and quality control. Over 270 PCT systems have been installed.
- A new next-generation PCT instrument, the Barocycler 2320EXTREME, was recently released.
- PBI is also developing ultra-shear technology to produce nanoemulsions for applications in food, pharmaceuticals, and other
This press release summarizes a collaboration between UCB and Domainex to develop cancer drugs targeting MEK protein. Using Domainex's protein engineering technology, they were able to identify a form of MEK suitable for structural analysis. This provided UCB with high-resolution structural information to design a novel class of MEK inhibitor molecules with potential to treat cancer. The collaboration validated Domainex's technology in rapidly solving challenges in identifying drug targets.
Global peptide cancer vaccine market & clinical pipeline insightRajesh Sarma
“Global Peptide Cancer Vaccine Market & Clinical Pipeline Insight” Report Highlights:
Introduction to Peptide cancer Vaccine
Mechanism of Action of Peptide Cancer Vaccine
Need of Peptide Cancer Vaccines
Clinical Trials Efficacy Study of Synthetic Peptide Analog Obtained From WT1 Oncoprotein
Wide Spectrum Action of Peptide Cancer Vaccines against Major Cancer
Global Peptide Cancer Vaccine Pipeline: 41 Vaccines
Global Peptide Cancer Vaccine Clinical Pipeline by Company, Indication & Phase
The document discusses Strand Genomics Inc., which offers genomic analysis and clinical interpretation software and services. It focuses on personalized medicine by using its StrandOmics platform to analyze genomic data and determine disease risks for individuals. StrandOmics aims to make genomic testing routine in medical care to help clinicians make more informed decisions. Strand has grown to over 200 scientists and serves over 2,000 labs and 100,000 patients. Its partnership with Health Care Global Enterprises successfully piloted cancer risk assessment and molecular diagnosis for over 50 patients in India.
A biomarker strategy aims to answer key clinical questions to support drug development through identifying and testing biomarkers. Developing a robust biomarker strategy can mitigate risks and inform clinical study design by generating testable hypotheses to bridge pre-clinical and clinical research. Effective biomarker strategies consider assay suitability, study design, and sample availability to reliably detect biomarkers and provide statistically meaningful results. Emerging technologies allow deeper interrogation of drugs and disease through multiplexed readouts to enhance biomarker discovery and clinical development.
This document provides information about an upcoming conference on immunogenicity taking place from June 12-13, 2017 in London. The conference will focus on standardizing immunogenicity methods, regulatory considerations, novel approaches to reducing immunogenicity, developments for biologic drugs and immunogenicity predictions, and emerging solutions. It lists the program agenda with topics such as predictive tools for immunogenicity, reporting clinically relevant data, cut point setting, EU guidance, ADA-dependent reactions, personalizing therapy, tolerogenic nanoparticles, and a panel on human versus humanized antibodies. Speakers are from organizations like Regeneron, NIBSC, EpiVax, Novartis, Abbvie, Merck, Roche, and Immun
The document discusses the potential for genetic testing in sports. It provides examples of genes linked to athletic performance, such as the ACTN3 gene which is associated with sprint performance. Countries like Uzbekistan are exploring genetic screening programs to identify children suited for certain sports. However, genes only explain some variability in athletic traits, as environment and training also play large roles. While certain physical attributes are genetically determined, such as height, other factors like speed can be improved through training, but individual ability to gain benefits from practice is also genetic. Overall, the document examines both the genetic and non-genetic influences on athleticism and the emerging use of genetics in sports identification and training programs.
This document discusses how in vivo imaging can be used to understand the distribution of candidate compounds in the body. It provides examples of how various imaging modalities such as positron emission tomography (PET), near infrared imaging, and mass spectrometry imaging can be used to track the accumulation of compounds in organs, penetration into tissues, and ability to cross barriers like the blood brain barrier. The document emphasizes how imaging can accelerate drug development by providing visualization of biological processes and quantifying pharmacokinetics, target engagement, and toxicity.
This document provides information about the 3rd Annual Conference on Drug Discovery Chemistry hosted by SMi Group. The conference will take place on March 18-19, 2019 in London, UK, with a half-day workshop on March 20. Key speakers will discuss topics such as novel drug modalities, targeting difficult proteins, using artificial intelligence in drug discovery, and optimizing drug discovery techniques. Attendees can learn about recent advances, network with industry leaders, and explore strategic partnerships. Discounts are available for early registration.
World ADC Frankfurt 2015 - sample brochureWorld ADC
The World ADC Frankfurt meeting has been established with the simple mission of speeding up the development of more potent and safe antibody drug conjugates.
Learn not only how to make an ADC, but how to make a great one. With insights on numerous novel payload technologies, robust strategies for preclinical evaluation and emerging clinical data, there is no better opportunity to accelerate your research.
We can aid decision making from the pre-clinical to the clinical setting, supporting line of sight to the clinic, by identifying and translating crucial biomarker approaches into the real world.
Ourotech is developing a hydrogel that mimics tumor microenvironments to test cancer drug resistance outside the body. Their solution involves obtaining tumor samples, growing them in a 96-well plate using the proprietary hydrogel, testing drug and combination treatments, and calculating human dosages. This allows personalized cancer treatment by determining the most effective drugs without trial and error. They have proof of concept data showing their hydrogel can better predict drug resistance compared to other methods. With $1.5M funding, they plan to finish preclinical trials, seek FDA clearance, generate revenue from pharmaceutical clients, and further develop the technology.
The document summarizes the work and goals of OncoPlex Diagnostics, a biotechnology company that uses mass spectrometry and liquid tissue technology to develop cancer diagnostic assays. It thanks various mentors and colleagues for their support of the author's internship. OncoPlex aims to establish standardized protein profiling as the standard for personalized cancer treatment by overcoming challenges such as physician education and product differentiation. The marketing department seeks to increase awareness of OncoPlex's technology by creating deliverables like sales sheets and letters for physicians.
This document announces a professional development session on the pharmaceuticals dashboard for 2021. It will discuss topics like uncertainty in quality, the future of manufacturing and regulations, and competitiveness with trade barriers. The session aims to help professionals mature their skills and align with emerging expectations. It will use tutorials, discussions, examples and case studies. Participant assessment will be confidential. The session facilitators have extensive regulatory experience in Pakistan and international agencies. It will be held on December 19th in Karachi with a small group size.
The Cell Therapy Catapult was established to help grow the UK cell therapy industry by providing facilities, expertise, and funding for collaboration between researchers and industry. It has laboratories and teams working on process development, clinical trials, and business development. In its first year it has over 60 staff and is engaged in both small and large collaborative projects. The goal is to deliver life-changing cell therapies and investible projects that help establish UK leadership in this industry.
SMi Group's Adaptive Designs in Clinical Trials conferenceDale Butler
This document summarizes an upcoming conference on adaptive designs in clinical trials taking place from April 20-21, 2015 in London. The conference will focus on topics such as Bayesian adaptive designs, subgroup selection in clinical trials, integrating real-world patient data into adaptive trials, and designing biomarker-driven multi-arm multi-stage cancer trials. Speakers will discuss challenges with adaptive designs and their use in different therapeutic areas like neurodegenerative diseases. Participants can also register for optional half-day workshops on April 22nd focusing on Bayesian clinical trial designs and navigating international regulatory landscapes for adaptive trials.
This is part of the MaRS BioEntrepreneurship series.
Speaker: Lynne Zydowsky, Ph.D., Managing Principal Zydowsky Consultants
* Explore the development of regulated drugs and devices
* Understand where and how value is generated in the pharmaceuticals industry
* Appreciate the interplay between science and business in a biotech company
To download a copy of the audio for this presentation, please go to:
http://www.marsdd.com/bioent/oct16
For the event blog and Q+A, please see:
http://blog.marsdd.com/2006/10/17/bringing-together-art-and-science/
This document provides information about an upcoming conference on immunogenicity taking place June 13-14, 2016 in London. It lists the schedule, speakers, and topics to be covered over the two days. The conference will explore approaches to standardizing immunogenicity assays, unwanted immunogenicity, integrating immunogenicity risk data to predict clinical outcomes, and other topics related to assessing and reducing the immunogenicity of biotherapeutics. Registration discounts are available by March 31st or April 29th. The conference is aimed at accelerating the commercialization of next generation biotherapeutics by adopting advanced immunogenicity assessments.
This document provides information about an upcoming conference on immunogenicity to be held June 13-14, 2016 in London. It includes an overview of the conference sessions and speakers. The sessions will cover topics such as approaches to standardizing drug level and anti-drug antibody assays, unwanted immunogenicity, integrating immunogenicity risk data, immunogenicity of biologics and biosimilars, and the role of aggregation in immunogenicity. There will also be two half-day post-conference workshops on June 15 on standardizing assays for biotherapeutics and unwanted immunogenicity from the bench to the bedside. The conference is aimed at accelerating development and approval of next generation biotherapeutics by adopting
SMi’s 3rd annual conference
Immunogenicity
13th and 14th June 2016, Holiday In Kensington Forum, London, UK.
Immunogenicity of an antigen is frequently encountered in the context of vaccine development, an area of intense interest currently due to the emergence or re-emergence of infectious pathogens with the potential for worldwide spread. With the global vaccine market expected to reach $84.44 billion by 2022, now is the time engage with industry experts to addresses the real challenges with immunogenicity including assay assessment, the role of aggregation, the introduction of nanobodies and many more!
For further information or to register please visit the event website www.immuno.co.uk or contact Matthew Apps on +44 (0) 207 827 6093 or mapps@smi-online.co.uk
This document provides information about the 4th Annual Conference on Cancer Vaccines to be held on September 16-17, 2015 in London. Professor Farzin Farzaneh of Kings College London will chair the conference. Key topics to be addressed include tumour genetic heterogeneity in immunotherapy, combination therapies to advance immune-oncology vaccines, and developments in targeted and personalized cancer treatments. There will be presentations from industry and academic leaders in the field.
This document provides information about an upcoming conference on immunogenicity hosted by SMi from July 14-16, 2014 in London, UK. The conference will focus on assessing early risks of immunogenicity, clinical implications, and strategies for evaluating and designing biologic therapeutics. Speakers will discuss topics like predictive tools for immunogenicity, inducing immunological tolerance, the immunogenicity of biosimilars, and more. The document also advertises two half-day post-conference workshops on July 16 about the clinical impact of immunogenicity and predictive tools, and the immunogenicity of biosimilars.
SMi Group's Cancer Vaccines 2015 conferenceDale Butler
This document summarizes a conference on cancer vaccines taking place in September 2015 in London. The conference will address topics such as tumour genetic heterogeneity in immunotherapy, understanding the angiogenic process in tumours, and developing RNA vaccines and combination therapies to advance immune-oncology. A keynote speech will discuss using personalized dendritic cell vaccines to mobilize the immune system against solid tumour targets. The conference features workshops, speakers from industry and academia, and discussions on advancing personalised cancer treatment and improving targeted responses to tumours through immunotherapy and vaccine development.
This document provides an agenda for the 2nd annual conference on immunogenicity taking place from June 29-30, 2015 in London. The conference will focus on understanding and modulating immunity in therapeutics, and exploring techniques to induce tolerance. It will include sessions on clinical directions, assays and assessments, with speakers from industry and academia. An interactive workshop on tools for early immunogenicity risk assessment will also be held on July 1.
This document summarizes an upcoming conference on superbugs and superdrugs taking place March 25-26, 2015 in London. The conference will focus on the latest developments in antibacterial therapies, funding, and partnerships to address antibiotic resistance. Over the two days, the conference will feature speakers from industry and academia discussing topics such as new business models for antibiotic development, clinical trials of new treatments, and partnerships between government and private organizations. Attendees can choose from two pre-conference workshops on designing antimicrobials for future needs and licensing an antibiotic. The conference is aimed at professionals involved in antibiotic research, development and related fields.
This document is a program for the 3rd annual ADC Summit 2014 conference on antibody-drug conjugates taking place from May 19-21, 2014 in London. The conference will feature presentations from industry experts on topics related to developing antibody-drug conjugates, including payloads, linkers, manufacturing, and clinical trials. Attendees can learn about the latest developments and network with other professionals in the field. A pre-conference workshop on May 21st will focus on early phase development considerations for antibody-drug conjugates to support first-in-human clinical trials.
Providing a focal point to push industry collaboration through updates on clinical advancements and investment opportunities, SMi presents the 20th annual Superbugs & Superdrugs conference which will return to Central London on 19th and 20th March 2018.
The threat of AMR is regularly making front page news but what is the industry actually doing? Are drug manufacturers any closer to finding a solution and how is the government helping? These will be just some of the questions answered through powerful keynote addresses delivered by an expert panel of scientific leaders, drug discovery specialists and government bodies such as MHRA and DNDi.
This document provides information about the 20th Annual Superbugs & Superdrugs conference on tackling antimicrobial resistance that will take place on March 19-21, 2018 in London. The conference will feature presentations on funding and regulatory approaches for new antibiotic development, strategies to combat resistant pathogens, and research on novel antibiotic candidates and alternatives. A half-day workshop on March 21st will provide an overview of using animal models in pre-clinical drug development.
This document provides information about a cancer vaccines conference, including two pre-conference workshops on cancer vaccines and combination therapies. The conference will take place September 20-22, 2016 in London and focus on the latest advances in cancer vaccine development and commercialization. It lists the agenda and speakers for the two days of the main conference, which will cover topics like RNA-based vaccines, biomarkers, clinical trials, and combination therapies. Registration discounts are available before certain dates. The workshops on September 20th will address how cancer vaccines can work with and without other treatments to maximize efficacy against cancer.
SMi Group's 5th annual Cancer Vaccines 2016 conferenceDale Butler
This document provides information about a cancer vaccines conference, including two pre-conference workshops, being held on September 20-22, 2016 in London. The conference will focus on the latest advances in cancer vaccine development and preparation for commercialization of immunotherapy breakthroughs. The workshops on September 20th will address cancer vaccines and combination therapies as well as active immune therapy strategies for cancer. The two-day main conference on September 21-22nd will include sessions on biomarkers, dendritic cell vaccines, personalized therapies, RNA vaccines, and targeting strategies. Speakers will represent academic institutions and companies developing cancer immunotherapy technologies and therapies.
SMi Group's Pharmaceutical Microbiology East Coast 2019 Dale Butler
This document provides information on the Pharmaceutical Microbiology East Coast conference taking place from April 10-11, 2019 in Boston, USA. It includes details on registration, chairpersons, key speakers and their topics. The conference will discuss challenges in pharmaceutical microbiology such as regulatory changes, environmental monitoring, rapid methods and sterility assurance. There will also be workshops on April 12th on mold contamination challenges and microbiological control using vapor phase hydrogen peroxide bio-decontamination. The event is aimed at professionals working in pharmaceutical microbiology.
This document provides information about the ADC Summit conference to be held on May 23-24, 2016 in London. It includes:
- An agenda for the two-day conference featuring presentations and workshops on topics related to antibody-drug conjugates (ADCs), including developments, innovations, challenges and lessons learned.
- Information about two half-day post-conference workshops on May 25th regarding ADC payloads and developments in high potency API manufacturing.
- Details on registration, discounts, speakers, sponsors and exhibition opportunities for the conference.
This document provides information about the ADC Summit conference to be held on May 23-24, 2016 in London. It includes:
- An agenda for the two-day conference featuring presentations and workshops on topics related to antibody-drug conjugates (ADCs), including developments, innovations, challenges and lessons learned.
- Information about two half-day post-conference workshops on May 25th regarding ADC payloads and developments in high potency API manufacturing.
- Details on registration, discounts, speakers, sponsors and exhibition opportunities for the conference.
2nd Annual Oncology Asia
Date: 7 – 9 September 2015 | Sheraton Miyako, Tokyo, Japan
www.oncologyasia.com
The 2nd Annual Oncology Asia zeroes in on the latest cutting edge developments in oncology drug discovery and late phase strategies to get oncology drugs to market faster! Under the Drug Discovery track, this conference will discuss latest immune checkpoint inhibitor combinations, preclinical development trends, novel biomarkers and oncology drug development case studies in Asia. Under the late phase track, it will discuss pricing for success, global and regional commercialization case studies, healthcare policy updates and pricing for success.
Find out about the latest drug discovery trends along with latest strategies for global and regional commercialization at the ONLY senior industry gathering focused on advancing cutting edge oncology R&D and commercialization strategies for Asia in Tokyo, Japan!
SMi Group's Pharma Microbiology East Coast 2019 - updated Feb 2019Dale Butler
This document provides information about the Pharmaceutical Microbiology East Coast conference taking place from April 10-12, 2019 in Boston, USA. The conference will discuss best practices and techniques for tackling microbial control challenges in the pharmaceutical industry. Over the two-day conference and optional workshops on the third day, topics will include regulatory considerations, environmental monitoring, rapid microbial methods, sterility assurance, case studies, and risk mitigation strategies. Speakers will represent major pharmaceutical companies and provide insights on the latest industry issues and solutions. Attendees can gain expertise on key microbiological topics relevant for pharmaceutical manufacturing and product development.
SMi Group's 8th annual Advances in Cell Based AssaysDale Butler
This document provides information about two half-day post-conference workshops on November 12, 2015 following the Advances in Cell Based Assays conference on November 10-11, 2015. Workshop A will focus on the latest generation microscopes for live cell imaging in high-throughput, high-content, and high-content analytical assays, featuring an interactive session with Nikon, UK. Workshop B will explore applying tissue engineering to develop 3D cell-based assays, focusing on generating in vitro disease models, led by Associate Professor Felicity Rose. Both workshops aim to discuss cutting-edge technologies and their applications to advance cell and tissue-based screening assays.
Similar to SMi Group's Immuno-Oncology 2018 conference (20)
SMi Group's Pharmaceutical Microbiology West Coast 2020 conferenceDale Butler
This document provides information on the Pharmaceutical Microbiology West Coast conference happening June 17-19, 2020 in San Diego. It outlines the chairs, speakers, highlights and agenda for the event. The conference will focus on novel approaches and best practices for tackling current industry contamination control challenges, and will include sessions on contamination control, guidance and regulations, detection and identification methods, and supporting pharmaceutical facilities and novel therapeutics. There will also be an optional pre-conference workshop on data integrity in environmental monitoring.
SMi Group's Pre-filled Syringes West Coast 2020 conferenceDale Butler
This document provides an agenda for the 5th annual Pre-Filled Syringes West Coast conference taking place June 15-17, 2020 in San Diego, CA. The conference will focus on innovations in device design and technology, advances in human factors engineering, combination product regulatory insights, and design controls and risk management. It will feature presentations from industry leaders at companies like Genentech and AstraZeneca as well as regulators from the FDA. There will also be two post-conference workshops on June 17th focusing on navigating FDA requirements for connected devices and digital health, and post-market safety reporting for combination products.
SMi Group's Military Robotics and Autonomous Systems USA 2020 conferenceDale Butler
This document advertises the Military Robotics and Autonomous Systems USA conference happening on June 22-23, 2020 in Arlington, Virginia. Attendees can save $400 by registering by February 28, $200 by registering by March 31, and $100 by registering by April 30. The conference will discuss topics like US Army robotics programs, Australian Army robotics development, unmanned vehicle programs, robotics supporting warfighters' mobility and sustainability, and integrating robotics into ground formations. Speakers will include representatives from the US and Australian militaries as well as academics working on relevant research.
SMi Group's Future Soldier Technology USA 2020 conferenceDale Butler
The document announces the 2nd Annual Future Soldier Technology USA conference on June 8-10, 2020 in Arlington, Virginia. The conference will focus on modernizing equipment for dismounted soldiers and marines, and feature speakers from the US and other militaries involved in soldier technology programs. Over 150 attendees are expected to discuss initiatives like NGSW-AR/R/FC, ISSP, and manned-unmanned teaming to enhance soldier lethality, mobility, and situational awareness.
SMi Group's Military Space USA 2020 conferenceDale Butler
This document provides an agenda for the 2nd Annual Military Space USA Conference supporting the US military space enterprise. The conference will include presentations from senior leaders in the US Space Force, Air Force, and other allied militaries on topics such as space acquisition reform through SMC 2.0, training the future space warfighting force, and leveraging disruptive commercial space technologies. A separate focus day will explore experimental smallsat capabilities, export controls for space technologies, advanced propulsion concepts, using LEO mega-constellations for bandwidth, in-orbit manufacturing, and accelerating commercial innovation. The event aims to connect disruptors and innovators with government to integrate new technologies rapidly into military space operations.
This document summarizes a conference focused on helicopter technology for Central and Eastern Europe being held in Budapest, Hungary on May 20-21, 2020. It will feature keynote speeches from military leaders from Hungary, Slovakia, Romania, Germany, and Croatia on developments and modernization efforts of their national helicopter fleets. Technical experts from the US, UK, Netherlands, and Czech Republic will also present. Sessions will discuss regional cooperation and interoperability, training standards, and enhancing capabilities like search and rescue. The goal is focused discussion on challenges facing helicopter program managers and informal networking for participants.
This document provides information about an upcoming conference on future armoured vehicles in Central and Eastern Europe in 2020. It outlines early registration discounts that decrease over time, as well as special rates for military and government representatives. The document details benefits of attending the conference, including hearing updates from armed forces in the region. It lists speakers from various countries who will discuss topics like armoured vehicle programmes, enhancing capabilities, and ensuring interoperability. The agenda outlines presentations over two days covering issues like future infantry fighting vehicles, enhancing mechanization capabilities, and modernizing ground platforms. The document promotes sponsorship opportunities at the event.
SMi Group's Unmanned Maritime Systems 2020 conferenceDale Butler
This document provides information about the 4th Annual Unmanned Maritime Systems conference taking place on April 13-14, 2020 in London. It discusses key reasons to attend like hearing from naval officers on integrating unmanned assets and learning about updates on unmanned platforms, anti-submarine warfare, mine countermeasures, and technological innovation. The agenda outlines presentations and speakers from military organizations like the Royal Navy, US Navy, Spanish Navy, and NATO who will discuss topics like developing unmanned systems, accelerating unmanned technologies, and using unmanned systems for mine countermeasure operations.
SMi Group's Military PNT 2020 conferenceDale Butler
The document summarizes the agenda for the "Military PNT 2020" conference to be held on May 18-19 in London. The event highlights include briefings from the US DoD on GPS and NTS-3 programs, understanding requirements for operating in degraded PNT environments, and engaging with industry and military leaders. The agenda covers topics such as UK PNT strategies, warfighter PNT considerations, legal perspectives on PNT resilience, and GNSS interference case studies. Keynote speakers include representatives from the US Air Force, Lockheed Martin, UK MoD, DGA, NPL, and BHO Legal.
This document provides an agenda for the Defence Aviation Safety conference taking place on April 23-24, 2020 in London. The agenda includes keynote presentations and panels on topics related to ensuring safety across defence aviation programs and platforms. Speakers will represent organisations such as the UK Ministry of Defence, US Air Force, German Military Aviation Authority, and NATO. Presentation topics will cover safety priorities, certification processes, training, accident investigation and lessons learned. A closing panel on day two will discuss the challenges of ensuring military aviation safety and cyber resilience.
SMi Group's Pre-filled Syringes East Coast 2020 Dale Butler
This document announces an interactive workshop on combination product development taking place on April 29th, 2020 in Boston, USA. The workshop will consist of three sessions focused on key topics in combination product development: combination product development strategies, drug delivery device testing solutions, and human factors validation studies. Speakers will include experts from major pharmaceutical companies such as AstraZeneca, Eli Lilly, Biogen, and regulatory agencies. The workshop aims to provide attendees insights and strategies for navigating challenges in combination product development from concept to approval.
SMi Group's Air Mission Planning and Support 2020Dale Butler
The document announces an upcoming conference on "Maximising Air Power through the Development and Integration of Innovative Support Systems" to be held in London on April 21-22, 2020. The conference will examine developments in air mission planning and focus on data management, fifth generation integration, and multi-domain command and control. It will feature expert military speakers from countries like the UK, US, Canada, France, Hungary, and Belgium representing air forces, NATO, and DARPA to discuss challenges and solutions.
SMi Group's Military Robotics and Autonomous Systems 2020 Dale Butler
This document provides information about the 3rd Annual Military Robotics and Autonomous Systems conference taking place on April 1-2, 2020 in London. It outlines the key topics to be discussed including UK and international perspectives on robotic and autonomous systems programs and strategies. Speakers will address topics such as unmanned ground vehicle development, autonomy for military robotic systems, and manned-unmanned teaming. The conference will explore delivering quality robotic systems to enhance operational effectiveness and discuss technology demonstrations.
This document advertises the 6th Annual Future Soldier Technology conference taking place March 9-11, 2020 in London. The conference will focus on dismounted soldier and marine technology, discussing key areas like dismounted capability. Military, procurement, and research experts from around the world will present on their soldier programs, challenges, and successes. Attendees can learn the latest developments, network with key speakers and decision makers, and gather intelligence to inform their projects. The conference aims to allow information sharing on equipping soldiers to maintain an advantage against evolving adversaries.
This document provides information about the 5th Annual Defence Logistics Central & Eastern Europe conference taking place on March 3-4, 2020 in Budapest, Hungary. The summary includes:
- The conference will bring together senior military, government, and industry personnel from Central and Eastern Europe to discuss developments in defence logistics and increase cooperation in the region.
- Over the two days, there will be keynote briefings and panels on topics like modernizing logistics structures, interoperability, operational capabilities of country logistics divisions, and industry roles. Speakers will represent militaries like Hungary, Czech Republic, Poland, and industry sponsors.
- Attendees can benefit from networking opportunities and learning about log
The document announces Space Week, consisting of the Small Satellites Conference from April 27-28 and the Military Space Situational Awareness Conference from April 29-30 in London. It provides details on the conferences, including chairpersons, speakers from various space agencies, companies, and militaries, and topics to be discussed such as small satellites, space insurance, disruptive approaches to space, space data, and military space situational awareness. The document aims to invite colleagues to participate in Space Week to explore developments in small satellites and how to track and manage space assets.
SMi Group's Superbugs and Superdrugs 2020 conferenceDale Butler
This document provides information about the Superbugs & Superdrugs conference on March 30-31, 2020 in London. The conference will focus on non-traditional approaches to fighting antimicrobial resistance and will feature speakers from companies and organizations working on alternatives to antibiotics, including those developing antibacterial proteins, agents that neutralize bacterial virulence, direct lytic agents, and immunomodulatory therapies. It provides details on the agenda, speakers, workshops, registration and sponsorship opportunities.
SMi Group's AI in Drug Discovery 2020 conferenceDale Butler
This document provides information about an upcoming conference on AI in Drug Discovery taking place from March 16-17, 2020 in London, UK. It includes details about the program, speakers, registration fees and deadlines. The conference will explore how machine learning and AI are being applied across the drug discovery process, from compound design and virtual screening to toxicity prediction. There will be case studies presented from major pharmaceutical companies on their experience integrating AI. The document also advertises sponsorship opportunities for the event.
How to Fix the Import Error in the Odoo 17Celine George
An import error occurs when a program fails to import a module or library, disrupting its execution. In languages like Python, this issue arises when the specified module cannot be found or accessed, hindering the program's functionality. Resolving import errors is crucial for maintaining smooth software operation and uninterrupted development processes.
हिंदी वर्णमाला पीपीटी, hindi alphabet PPT presentation, hindi varnamala PPT, Hindi Varnamala pdf, हिंदी स्वर, हिंदी व्यंजन, sikhiye hindi varnmala, dr. mulla adam ali, hindi language and literature, hindi alphabet with drawing, hindi alphabet pdf, hindi varnamala for childrens, hindi language, hindi varnamala practice for kids, https://www.drmullaadamali.com
This presentation was provided by Steph Pollock of The American Psychological Association’s Journals Program, and Damita Snow, of The American Society of Civil Engineers (ASCE), for the initial session of NISO's 2024 Training Series "DEIA in the Scholarly Landscape." Session One: 'Setting Expectations: a DEIA Primer,' was held June 6, 2024.
বাংলাদেশের অর্থনৈতিক সমীক্ষা ২০২৪ [Bangladesh Economic Review 2024 Bangla.pdf] কম্পিউটার , ট্যাব ও স্মার্ট ফোন ভার্সন সহ সম্পূর্ণ বাংলা ই-বুক বা pdf বই " সুচিপত্র ...বুকমার্ক মেনু 🔖 ও হাইপার লিংক মেনু 📝👆 যুক্ত ..
আমাদের সবার জন্য খুব খুব গুরুত্বপূর্ণ একটি বই ..বিসিএস, ব্যাংক, ইউনিভার্সিটি ভর্তি ও যে কোন প্রতিযোগিতা মূলক পরীক্ষার জন্য এর খুব ইম্পরট্যান্ট একটি বিষয় ...তাছাড়া বাংলাদেশের সাম্প্রতিক যে কোন ডাটা বা তথ্য এই বইতে পাবেন ...
তাই একজন নাগরিক হিসাবে এই তথ্য গুলো আপনার জানা প্রয়োজন ...।
বিসিএস ও ব্যাংক এর লিখিত পরীক্ষা ...+এছাড়া মাধ্যমিক ও উচ্চমাধ্যমিকের স্টুডেন্টদের জন্য অনেক কাজে আসবে ...
Exploiting Artificial Intelligence for Empowering Researchers and Faculty, In...Dr. Vinod Kumar Kanvaria
Exploiting Artificial Intelligence for Empowering Researchers and Faculty,
International FDP on Fundamentals of Research in Social Sciences
at Integral University, Lucknow, 06.06.2024
By Dr. Vinod Kumar Kanvaria
Main Java[All of the Base Concepts}.docxadhitya5119
This is part 1 of my Java Learning Journey. This Contains Custom methods, classes, constructors, packages, multithreading , try- catch block, finally block and more.
LAND USE LAND COVER AND NDVI OF MIRZAPUR DISTRICT, UPRAHUL
This Dissertation explores the particular circumstances of Mirzapur, a region located in the
core of India. Mirzapur, with its varied terrains and abundant biodiversity, offers an optimal
environment for investigating the changes in vegetation cover dynamics. Our study utilizes
advanced technologies such as GIS (Geographic Information Systems) and Remote sensing to
analyze the transformations that have taken place over the course of a decade.
The complex relationship between human activities and the environment has been the focus
of extensive research and worry. As the global community grapples with swift urbanization,
population expansion, and economic progress, the effects on natural ecosystems are becoming
more evident. A crucial element of this impact is the alteration of vegetation cover, which plays a
significant role in maintaining the ecological equilibrium of our planet.Land serves as the foundation for all human activities and provides the necessary materials for
these activities. As the most crucial natural resource, its utilization by humans results in different
'Land uses,' which are determined by both human activities and the physical characteristics of the
land.
The utilization of land is impacted by human needs and environmental factors. In countries
like India, rapid population growth and the emphasis on extensive resource exploitation can lead
to significant land degradation, adversely affecting the region's land cover.
Therefore, human intervention has significantly influenced land use patterns over many
centuries, evolving its structure over time and space. In the present era, these changes have
accelerated due to factors such as agriculture and urbanization. Information regarding land use and
cover is essential for various planning and management tasks related to the Earth's surface,
providing crucial environmental data for scientific, resource management, policy purposes, and
diverse human activities.
Accurate understanding of land use and cover is imperative for the development planning
of any area. Consequently, a wide range of professionals, including earth system scientists, land
and water managers, and urban planners, are interested in obtaining data on land use and cover
changes, conversion trends, and other related patterns. The spatial dimensions of land use and
cover support policymakers and scientists in making well-informed decisions, as alterations in
these patterns indicate shifts in economic and social conditions. Monitoring such changes with the
help of Advanced technologies like Remote Sensing and Geographic Information Systems is
crucial for coordinated efforts across different administrative levels. Advanced technologies like
Remote Sensing and Geographic Information Systems
9
Changes in vegetation cover refer to variations in the distribution, composition, and overall
structure of plant communities across different temporal and spatial scales. These changes can
occur natural.
How to Manage Your Lost Opportunities in Odoo 17 CRMCeline George
Odoo 17 CRM allows us to track why we lose sales opportunities with "Lost Reasons." This helps analyze our sales process and identify areas for improvement. Here's how to configure lost reasons in Odoo 17 CRM
How to Add Chatter in the odoo 17 ERP ModuleCeline George
In Odoo, the chatter is like a chat tool that helps you work together on records. You can leave notes and track things, making it easier to talk with your team and partners. Inside chatter, all communication history, activity, and changes will be displayed.
Executive Directors Chat Leveraging AI for Diversity, Equity, and InclusionTechSoup
Let’s explore the intersection of technology and equity in the final session of our DEI series. Discover how AI tools, like ChatGPT, can be used to support and enhance your nonprofit's DEI initiatives. Participants will gain insights into practical AI applications and get tips for leveraging technology to advance their DEI goals.
Pride Month Slides 2024 David Douglas School District
SMi Group's Immuno-Oncology 2018 conference
1. www.immuno-oncology-conference.com
Register online or fax your registration to +44 (0) 870 9090 712
or call +44 (0) 870 9090 711
A: Strategic Competitive Intelligence in the
Immuno-Oncology space
Workshop Leaders:
Timos Papagatsias, CEO, LucidQuest Ventures
08.30 - 12.30
B: Could the Microbiome boost cancer immunotherapy?
Workshop Leaders:
Shahram Lavasani, CEO, ImmuneBiotech
Ramin Massoumi, Principal Investigator, Lund University
13:30 - 17:00
PLUS TWO INTERACTIVE HALF-DAY PRE-CONFERENCE WORKSHOPS | TUESDAY 25TH SEPTEMBER 2018, COPTHORNE TARA HOTEL, LONDON, UK
SMi Pharma
@SMiPharm
#immunooncologySMi
CHAIR FOR 2018:
• James Legg, Vice President R&D, Crescendo Biologics
KEY SPEAKERS INCLUDE:
• Andrew Exley, Medical Assessor, MHRA
• Harry Smith, Medical Scientist, Gilead Sciences
• Grace Macaulay, Global Safety Physician Patient Safety
Oncology, MedImmune
• David Giljohan, CEO, Exicure
• Kandeepan Ganeshalingam, Executive Director, Oncology
Therapeutic Area Head, European Clinical Development,
MSD
• Rochana Wickramasinghe, Director of Oncology Evaluation,
AstraZeneca
HIGHLIGHTS IN 2018:
• Learn about targeting immune checkpoints with
Humabody VH Therapeutics
• Discover the recent advances in providing durable disease
control with Keytruda as an anti-cancer therapy
• Discuss the tumour mutation burden and the potential of its
use as an indication of treatment choice
• Develop an understanding of unwanted immunogenicity
and functionality testing of immuno-oncology drugs
• Gain insight into new techniques, such as the emerging
applications of liquid biopsies, in Immuno-Oncology
WORKSHOPS: 25TH
CONFERENCE: 26TH-27TH
SEPT
2018COPTHORNE TARA HOTEL, LONDON, UK
SMi presents the inaugural Conference on…
Immuno-Oncology
Propagating thought-provoking discussions on
novel targeted cancer therapies
REGISTER BY 30TH APRIL AND SAVE £400
REGISTER BY 31ST MAY AND SAVE £300
REGISTER BY 29TH JUNE AND SAVE £200
2. Immuno-Oncology
Day One | Wednesday 26th September 2018 www.immuno-oncology-conference.com
08.30 Registration & Coffee
09.00 Chairman’s Opening Remarks
James Legg, Vice President R&D, Crescendo Biologics
KEYTRUDA, IMMUNE CHECKPOINTS AND ONCOLYTIC VIRUSES
9.10 Keytruda: anticancer therapy across a wide range of
malignancies
• Recent advances in providing durable disease control
• Innovative combination strategies to improve upon
monotherapy activity and overcome resistance
• Importance of patient selection in cancer immunotherapy
Kandeepan Ganeshalingam, Executive Director, Therapeutic Area
Head Oncology, Merck Sharp & Dohme
9.50 Targeting immune checkpoints with Humabody VH Therapeutics
• Crescendo Biologics’ development of Humabody VH
products, small highly adaptable and flexible proteins which
can be developed into differentiated therapeutics
• A description of Crescendo’s approach to developing
differentiated Immuno oncology therapeutics with several
examples of molecules in our research pipleline
• Case studies include a BiParatopic PD-1 inhibitor which shows
efficacy in an anti-PD-1 insensitive in vivo model, a BiSpecific
molecule inhibiting both PD-1 and LAG3 for overcoming
resistance or insensitivity to PD-1 inhibition and a Targeted IO
approach in which T-cell co-stimulation is focused away from
the periphery and into the tumour microenvironment in order to
improve the narrow therapeutic index observed with standard
T-cell agonist antibodies
James Legg, Vice President R&D, Crescendo Biologics Ltd
10.30 Morning Coffee
11.00 Enhanced cancer vaccine effectiveness with NKTR-214, a CD122-
biased cytokine
• NKTR-214 biases signalling through the IL-2 receptor pathway
to generate profound effector T-cell responses while reducing
regulatory T-cell activity in tumours
• Combination dosing of NKTR-214 dramatically enhances activity
of several tumour vaccine modalities in mouse models
• The unique profile of T-cell activity generated by NKTR-214 may
enable the next generation of tumour vaccines
Jonathan Zalevsky, Senior Vice President Biology & Preclinical
Development, Nektar Therapeutics
BISPECIFICS, PK-PD MODELING AND IMMUNOGENICITY
11.40 The use of Bispecific Antibodies to modulate anti-tumour
immune responses
• Bispecific antibodies: an attractive alternative to cancer
treatments combinations
• F-star’s approach to create bispecific mAb²
• In vitro and in vivo efficacy of F-star bispecific antibodies
targeting oncology pathway
Session reserved for F-Star (speaker to be confirmed)
12.20 Networking Lunch
13.30 Application of PK-PD modeling and simulation in development of
T-Cell redirecting antibodies
• Platform Target-Biologic-Effector Engagement Model
• Evaluation of key parameters (e.g. Target/T-cell affinity, E:T
Ratio) on Cytolysis and T-cell Activation
• Evolution of the developed platform model to Multi-specific
Biologics
• Preclinical-to-Clinical Translation
Aman Singh, PK-PD Scientist, Janssen
14.10 Unwanted immunogenicity and functionality testing of immuno-
oncology drugs
• Tools for early unwanted immunogenicity assessment: in silico
and in vitro assays
• In vitro functional testing to accelerate immune oncology drug
design
• Optimal early lead selection
Sofie Pattijn, Chief Technology Officer, ImmunXperts
14.50 Afternoon Tea
CAR-T CELLS AND THE TUMOUR MUTATION BURDEN
15.20 T4 CAR T cell immunotherapy of patients with refractory head and
neck cancer
• A CAR has been engineered using a promiscuous ligand that
engages 8 distinct ErbB dimer species
• Phase 1 evaluation has been initiated in patients with head and
neck cancer, using intra-tumoural delivery and phased dose
escalation to mitigate risk
• Thirteen patients have been safely treated to date, at doses of
up to 1Bn cells, without DLTs and with an efficacy signal evident
Caroline Hull, Research Associate, Kings College London
16.00 The tumour mutation burden and using this as an indication of
treatment choice
• The effect of a higher number of somatic mutations on the
susceptibility to treatment
• Why a higher somatic mutation rate increases the chance of
response to IO treatments
• How the tumour mutation burden can be harnessed to optimise
the effect of therapies
• The cut off points used and the validation of this point
Harry Smith, Medical Scientist, Gilead
16.40 Chairman’s Closing Remarks and Close of Day One
Register online at www.immuno-oncology-conference.com
SUPPORTED BY
SPONSORSHIP AND EXHIBITION OPPORTUNITIES
SMi offer sponsorship, exhibition, advertising and branding packages, uniquely tailored to complement your company’s marketing strategy. Prime
networking opportunities exist to entertain, enhance and expand your client base within the context of an independent discussion specific to your
industry. Should you wish to join the increasing number of companies benefiting from sponsoring our conferences please call:
Alia Malick on +44 (0) 20 7827 6168 or email: amalick@smi-online.co.uk
3. Immuno-Oncology
www.immuno-oncology-conference.com Day Two | Thursday 27th September 2018
08.30 Registration & Coffee
09.00 Chairman’s Opening Remarks
James Legg, Vice President R&D, Crescendo Biologics
COMBINATION THERAPIES
9.10 Combining cancer vaccines with T cell co-stimulatory
receptor agonists
• T cell co-stimulatory receptor agonists have had a modest
impact within the context of Immuno-Oncology
• In vitro and in vivo examples of enhanced potency within the
context of antigen-specific T cell priming
• Future directions and opportunities for academic / biotech
collaborations
Scott Robbins, Principal Scientist, MedImmune
9.50 IO/ADC combination therapies
• Combining ADC and IO therapies
• ADC/IO Case Studies
• IO/PBD-ADC combinations
- Immunomodulatory properties
- Synergy with immunotherapies
Philip Howard, Chief Scientific Officer, Spirogen
10.30 Morning Coffee
11.00 Innate Immune Activators- Spherical Nucleic Acid TLR9 in
combination with checkpoint inhibitors
• Spherical Nucleic Acids (SNAs) are 3D forms of DNA and RNA
that enter cells naturally
• SNAs can be used to potently activate Toll-like-receptor (TLR)
pathways
• Pre-clincal work has shown activity in Breast, Lung, Melanoma,
and Colorectal cancers in combination with checkpoint
inhibitors
• Phase I normal volunteer studies were begun in October 2017,
results of which will be shared
David Giljohann, CEO, Exicure Inc.
REGULATIONS AND SAFETY CHALLENGES
11.40 Human tissue research in the UK: ethics and regulation
• Ethical approval and regulation of Human Tissue research
• The roles of the Health Research Authority (HRA)
• The roles of Human Tissue Authority (HTA)
Christopher Perrett, Regulation Manager, Human Tissue Authority
12.20 Networking Lunch
13.30 Generating symbiosis with regulatory affairs in
Immuno-Oncology
• How are the regulations keeping up with innovation and
evolving therapeutic approaches?
• The differentiation between European vs American procedures
of approval
• Is there likely to be a gap between patients’ therapeutic
access, restricted by approval procedures
• What are the current barriers to entry in the market?
Andrew Exley, Medical Assessor, MHRA
14.10 Key safety challenges in cancer immunotherapy clinical trials
• Immunotherapy past, present, and future
• Checkpoint inhibitors
• Key safety challenges: immune-mediated AEs
• ESMO/ASCO guidelines
• Way forward: getting the right balance
• Conclusion
Grace Macaulay, Global Safety Physician, Patient Safety-
Oncology, MedImmune
14.50 Afternoon Tea
CLINICAL COLLABORATIONS AND LIQUID BIOPSIES
15.20 Clinical collaborations in IO — why do them and what pharma
looks for
• History of clinical collaborations in IO
• How IO clinical collaborations have changed the business
model for how pharma and biotech interact
• Why should biotechs enter into an IO clinical collaboration with
pharma?
• What does pharma look for in a biotech when deciding
whether or not to enter into a clinical collaboration?
Rochana Wickramasinghe, Evaluation Director, AstraZeneca
16.00 Emerging applications of liquid biopsies in immuno-oncology
• An introduction to the field of liquid biopsies will be given, and
the biology explored
• Technologies and platforms for circulating tumour DNA (ctDNA)
analysis will be outlined and appraised
• Clinical applications of liquid biopsies in oncology will be
explored
• Recent data on the use of liquid biopsies for monitoring
immunotherapy will be discussed
Jonathan Wan, MD, PhD Student, Cancer Research UK
16.40 Chairman’s Closing Remarks and Close of Day Two
Alternatively fax your registration to +44 (0)870 9090 712 or call +44 (0)870 9090 711
SUPPORTED BY
Want to know how you can get involved? Interested in promoting your services to this market?
Contact Lyudmyla Durneva, SMi Marketing on +44 (0) 20 7827 6088 or
email: ldurneva@smi-online.co.uk
4. HALF DAY PRE-CONFERENCE WORKSHOP A
Tuesday 25th September 2018
Copthorne Tara Hotel, London, UK
8.30 - 12.30
Strategic Competitive Intelligence
in the Immuno-Oncology space
Workshop Leader:
Timos Papagatsias, CEO, LucidQuest Ventures
Workshop overview:
This workshop will focus on how stakeholders can combine the
latest advancements in Strategic Competitive Intelligence in
order to uncover opportunities and threats for their companies
and brands in the Immuno-Oncology space. Workshop
participants will also be provided with a short step-by-step guide
on how to use competitive intelligence to generate actionable
insights which will help them gain a competitive advantage
over others.
Key benefits of attending:
• Learn about Strategic Competitive Intelligence and how to
generate actionable insights
• Understand how to most effectively conduct CI in the
Immuno-Oncology space and remain competitive
Agenda
08.30 Registration and coffee
09.00 Opening remarks and introductions
9.10 Session 1: Introduction to strategic competitive
intelligence
• What CI is, what it is not and how to do it
• What you can and what you cannot do with CI
• Evolution of CI and its tools
• Importance of CI in the I/O space
9.50 Session 2: How to gain or maintain a competitive
advantage in the I/O space, whether you are a
newcomer or established player
• What can you learn from your competitors and
the marketplace using CI in the I/O space?
• Using CI to support combination study design,
gain early insights in trial results, identify new
combination approaches, validate new targets,
develop modified patient journeys etc.
• Minimizing uncertainty in a rapidly moving space
• How to improve on databases using targeted
primary competitive intelligence
• How to use social media and social networks to
better monitor competitor activity and identify
emerging threats and opportunities
10.30 Morning Coffee
11.00 Session 3: “Future-proofing” your efforts by
identifying early warning signals and opportunities
for your company in I/O
• Short step-by-step guide / case study
11.40 Q&A
12.30 Closing Remarks and end of workshop
About the Workshop Leader:
Timos has over 10 years’ experience working as a strategy and
intelligence consultant across the Pharma / Biotech and the
Life Sciences Investment industries. He has advised 18 out of
20 top Pharma and Biotechnology companies and has also
worked with a large number of medium and small size firms on
multiple topics (market entry and market access optimization,
patient centricity, digital healthcare and social media, clinical
product development and trial design, brand positioning,
portfolio analysis etc.) across therapy areas and geographies.
He is currently the CEO of LucidQuest, a boutique strategic
intelligence consultancy that focuses both on traditional
therapy areas (oncology, haematology, immunology, CV/
Met, CNS etc.) as well as on developing insights into patient
centricity, digital healthcare / IoE and personalized medicine
(gene and cell therapies).
ORGANISATION SYNOPSIS:
LucidQuest provides strategic intelligence
and evidence-based investment insights
for the Life Sciences and other industries.
We partner with leading Pharma, Biotech
and Healthcare companies and consultancy firms, providing
support across multiple therapy areas (respiratory, CV & Met,
onco / haem, CNS, vaccines, gene and cell therapy etc.)
and also in the rapidly evolving Digital Healthcare / IoE space.
We further provide investment insights to hedge funds, PE, VC,
angel investors etc., leveraging our in-house and our network’s
scientific and commercial expertise.
5. HALF DAY PRE-CONFERENCE WORKSHOP B
Tuesday 25th September 2018
Copthorne Tara Hotel, London, UK
13.30 - 17.00
Could the Microbiome boost
cancer immunotherapy?
Workshop Leaders:
Shahram Lavasani, CEO, ImmuneBiotech
Ramin Massoumi, Principal Investigator, Lund University
Workshop overview:
The commensal microbiome is a key modulator of
host physiology and risk of diseases, including cancer
development and progression. Recent reports suggest
that the microbiome can modulate the efficacy of
anti-cancer treatment. This workshop will cover recent
advances in understanding of the complex role of
microbiome in health and disease and how microbes and
the microbiota may contribute to cancer development,
and responsiveness to cancer therapeutics. We will further
discuss the advantages and challenges of developing
microbiome based treatments.
Gain insights into:
• Understanding of the dynamics and function of the
human microbiome in health and disease
• Cancer and human microbiota
• Dysbiosis and Cancer Therapy
• Immunostimulation by the microbiome
• Microbial interventions
Agenda
13.30 Registration and coffee
14.00 Opening remarks and introductions
14.10 Session 1: The role of human microbiome in
health and disease
• Microbiome, a young and challenging field
• Dysbiosis, cause or consequence?
• Microbial education of the immune system
14.50 Session 2: Microbiome in cancer
development and therapy
• Dysbiosis and cancer
• The gut microbiome and immuno-oncology
• The impact on the action of Immune
checkpoint Inhibitors
• Microbiota targeted therapies and impact
on oncological treatment efficacy
• The benefits of the Probiotics
15:20 Morning Coffee
15.50 Session 3: What is the next step
• General discussions on the advantages and
challenges in development of microbiome
based therapies
16.30 Q&A
17.00 Closing Remarks and end of workshop
About the Workshop Leader:
Shahram Lavasani holds a PhD degree from Lund University
in Medical Inflammation Research where he studied
the immunoregulation and novel immunotherapies in
multiple sclerosis (MS) followed by two years of post doc at
department of the surgery at University hospital in Malmö/
Sweden. He is a skillful immunologist, with many years
of teaching and research expertise on gastrointestinal
complications in autoimmune and chronic inflammatory
diseases. Focusing on Gut-Brain axis he has pioneered
research in MS, which is an autoimmune disease of the
central nervous system, by demonstrating inflammation
and increased permeability in the gut and introduced
microbiota-basedtherapiesusingcombinationofprobiotic
bacteria. He is the founder of ImmuneBiotech, developed
a proprietary lactobacilli library and established accurate
and multiple selection technologies to screen and design
formulations for the optimal therapeutic management of
the diseases.
About the Organisation:
ImmuneBiotech discovers and develops
novel bacterial-based therapeutics
targeting the gut microbiota and the
immune system. The company has
access to an exclusive bacterial library,
established an advanced screening
platform and developed a unique
know-how to develop bacterial solutions
to modulate the microbiome also with
impact on the gut barrier function and
the immune system. The company´s GutMagnific™ has
shown great success in treatment of IBS and will soon be
launched on the market.
6. IMMUNO-ONCOLOGY
Conference: 26th -27th September 2018, Copthorne Tara Hotel, London, UK Workshops: 25th September 2018, Copthorne Tara Hotel, London, UK
4 WAYS TO REGISTER
FAX your booking form to +44 (0) 870 9090 712
PHONE on +44 (0) 870 9090 711
ONLINE at www.immuno-oncology-conference.com
POST your booking form to: Events Team, SMi Group Ltd,
1 Westminster Bridge Road, London, SE1 7XW
If you have any further queries please call the Events Team on tel +44 (0) 870 9090 711 or you can email them at events@smi-online.co.uk
Unique Reference Number
Our Reference P-295
Payment must be made to SMi Group Ltd, and received before the event, by one of
the following methods quoting reference P-295 and the delegate’s name. Bookings
made within 7 days of the event require payment on booking, methods of payment:
□ UK BACS Sort Code 300009, Account 00936418
□ Wire Transfer Lloyds TSB Bank plc, 39 Threadneedle Street, London, EC2R 8AU
Swift (BIC): LOYDGB21013, Account 00936418
IBAN GB48 LOYD 3000 0900 9364 18
□ Cheque We can only accept Sterling cheques drawn on a UK bank.
□ Credit Card □ Visa □ MasterCard □ American Express
SMi Group will apply surcharges to commercial cards
Please tick here □ if the card provided is not a commercial card
Card No: □□□□ □□□□ □□□□ □□□□
Valid From □□/□□ Expiry Date □□/□□
CVV Number □□□□ 3 digit security on reverse of card, 4 digits for AMEX card
Cardholder’s Name:
Signature: Date:
I agree to be bound by SMi’s Terms and Conditions of Booking.
Card Billing Address (If different from above):
DOCUMENTATION
I cannot attend but would like to Purchase access to the following Document Portal/
Paper Copy documentation. Price Total
□ Access to the conference documentation
on the Document Portal £499.00 + VAT £598.80
□ The Conference Presentations – paper copy £499.00 - £499.00
(or only £300 if ordered with the Document Portal)
PAYMENT
VAT
VAT at 20% is charged on the attendance fees for all delegates. VAT is also charged
on Document portal and literature distribution for all UK customers and for those EU
Customers not supplying a registration number for their own country here
CONFERENCE PRICES GROUP DISCOUNTS AVAILABLE
I would like to attend: (Please tick as appropriate) Fee TOTAL
□ Conference 2 Workshops £2697.00 + VAT £3236.40
□ Conference 1 Workshop □ A □ B £2098.00 + VAT £2517.60
□ Conference only £1499.00 + VAT £1798.80
□ 2 Workshops only £1198.00 + VAT £1437.60
□ 1 Workshop only □ A □ B £599.00 + VAT £718.80
PROMOTIONAL LITERATURE DISTRIBUTION
□ Distribution of your company’s promotional
literature to all conference attendees £999.00 + VAT £1198.80
The conference fee includes refreshments, lunch, conference papers, and access to
the Document Portal. Presentations that are available for download will be subject
to distribution rights by speakers. Please note that some presentations may not be
available for download. Access information for the document portal will be sent to
the e-mail address provided during registration. Details are sent within 24 hours post
conference.
□ Book by 30th April to receive £400 off the conference price
□ Book by by 31st May to receive £300 off the conference price
□ Book by 29th June to receive £200 off the conference price
EARLY BIRD
DISCOUNT
Please complete fully and clearly in capital letters. Please photocopy for additional delegates.
Title: Forename:
Surname:
Job Title:
Department/Division:
Company/Organisation:
Email:
If you would like to continue to receive email updates about our
events, please tick □
Company VAT Number:
Address:
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
Mobile:
Switchboard:
Signature: Date:
I agree to be bound by SMi’s Terms and Conditions of Booking.
ACCOUNTS DEPT
Title: Forename:
Surname:
Email:
Address (if different from above):
Town/City:
Post/Zip Code: Country:
Direct Tel: Direct Fax:
Payment: If payment is not made at the time of booking, then an invoice will be issued and must
be paid immediately and prior to the start of the event. If payment has not been received then
credit card details will be requested and payment taken before entry to the event. Bookings within
7 days of event require payment on booking. Access to the Document Portal will not be given until
payment has been received.
Substitutions/Name Changes: If you are unable to attend you may nominate, in writing, another
delegate to take your place at any time prior to the start of the event. Two or more delegates may
not ‘share’ a place at an event. Please make separate bookings for each delegate.
Cancellation: If you wish to cancel your attendance at an event and you are unable to send
a substitute, then we will refund/credit 50% of the due fee less a £50 administration charge,
providing that cancellation is made in writing and received at least 28 days prior to the start of the
event. Regretfully cancellation after this time cannot be accepted. We will however provide the
conferences documentation via the Document Portal to any delegate who has paid but is unable
to attend for any reason. Due to the interactive nature of the Briefings we are not normally able to
provide documentation in these circumstances. We cannot accept cancellations of orders placed
for Documentation or the Document Portal as these are reproduced specifically to order. If we
have to cancel the event for any reason, then we will make a full refund immediately, but disclaim
any further liability.
Alterations: It may become necessary for us to make alterations to the content, speakers, timing,
venue or date of the event compared to the advertised programme.
Privacy policy / Opt Out: For full details on our privacy policy please go to
http://smi-online.co.uk/privacy-legals/privacy-policy. If you no longer wish to receive email
updates you can opt out by going to the following webpage http://www.smi-online.co.uk/opt-out
Terms and Conditions of Booking
DELEGATE DETAILS
VENUE Copthorne Tara Hotel, London, UK
□ Please contact me to book my hotel
Alternatively call us on +44 (0) 870 9090 711,
email: events@smi-online.co.uk or fax +44 (0) 870 9090 712